文献速递临床微生物质量管理与危急值

临床分离株产碳青霉烯酶菌株的表型检测

Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates.
PubMed 文献 · J Clin Microbiol · 2018-10-25

本文综述了临床微生物实验室用于检测产碳青霉烯酶菌株(CPO)的表型方法,包括生长法(如改良Hodge试验和改良碳青霉烯灭活法)、水解法(如Carba NP试验和基质辅助激光解吸电离飞行时间质谱)以及侧流免疫层析法。尽管没有单一表型试验能满足理想试验的所有要求,但多种试验具有用户友好、经济、准确且适用于不同规模实验室的特点。

要点

  • 表型检测可确认碳青霉烯酶产生及酶类,指导治疗选择。
  • CPO传播需更严格感染控制,表型检测有助于识别。
  • 生长法、水解法和侧流免疫层析法是主要表型检测手段。

核心结论

  • 多种表型试验用户友好、经济、准确,适合各规模临床微生物实验室实施。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • 表型试验包括生长法(改良Hodge试验、改良碳青霉烯灭活法)、水解法(Carba NP试验、MALDI-TOF MS)和侧流免疫层析法。
  • 没有单一表型试验满足理想试验的所有规格。
  • 了解碳青霉烯酶产生及类别对治疗有指导意义,因某些药物对特定碳青霉烯酶有 preferential 活性。
  • CPO比非产碳青霉烯酶的碳青霉烯耐药菌更易在患者间传播,需更强化感染控制措施。

临床怎么用

  • 临床微生物实验室可根据需求选择用户友好、经济、准确的表型试验检测CPO。
  • 表型检测结果可指导碳青霉烯酶相关感染的治疗选择和感染控制措施。

局限性

  • 没有单一表型试验满足理想试验的所有规格。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The rapid spread of multidrug-resistant Gram-negative organisms constitutes one of the greatest challenges to global health. While Gram-negative organisms have developed several mechanisms to avert the bactericidal effects of commonly prescribed antibiotic agents, the increasing prevalence of carbapenemase-producing organisms (CPO) is particularly concerning given the rapid spread of mobile genetic elements containing carbapenemase genes, the limited treatment options for infections caused by these organisms, and the high mortality rates associated with CPO infections. Understanding if an organism is carbapenemase producing and, if so, the class of carbapenemase(s) produced has treatment implications, as some agents preferentially have activity against specific carbapenemases. Furthermore, CPO disseminate between patients with greater ease than non-CP-carbapenem-resistant organisms and warrant more intensive infection control measures than would be employed in the absence of carbapenemase production. Phenotypic assays currently used in clinical practice to detect CPO consist of the following: (i) growth-based assays which measure carbapenem resistance based on organism growth in the presence of a carbapenem antibiotic (e.g., modified Hodge test and modified carbapenem inactivation method), (ii) hydrolysis methods which detect carbapenem degradation products (e.g., Carba NP test and matrix-assisted laser desorption-ionization time of flight mass spectrometry), and (iii) lateral flow immunoassays which detect carbapenemase enzymes through the use of specific antibodies. Although there is no single phenotypic test that meets all specifications of the ideal test, as we describe in this review, there are a number of tests that are user-friendly, affordable, accurate, and feasible for implementation in clinical microbiology laboratories of all sizes.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Tamma PD, Simner PJ. Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates. J Clin Microbiol. 2018. PMID: 30158194. doi:10.1128/JCM.01140-18

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。